

Customer No. 22869  
Appl. No. 10/804,822  
July 2, 2007

Atty. Docket No. 135/003  
Supplemental Information Disclosure Statement

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In the application of: Lawrence W. STANTON et al.

Serial No.: 10/804,822

Filing Date: March 19, 2004

For: STANDARDIZATION OF GROWTH  
CONDITIONS FOR HUMAN EMBRYONIC  
STEM CELLS INTENDED FOR USE IN  
REGENERATIVE MEDICINE

Art Unit: 1632

Examiner: Shin Lin CHEN

Confirmation No. 7106

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

**MAIL STOP AMENDMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

The information listed in the accompanying form PTO/SB/08 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure under 37 C.F.R. § 1.56. The Examiner is requested to make this information of record in the application.

Applicants believe that this Information Disclosure Statement is being filed after the mailing date of a Final Office Action. A certification under 37 C.F.R. § 1.97(e)(1) is below.

I certify that each item of information contained in the Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

Customer No. 22869  
Appl. No. 10/804,822  
July 2, 2007

Atty. Docket No. 135/003  
Supplemental Information Disclosure Statement

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 C.F.R. § 1.56(b).

Please charge the fee of \$180 to Deposit Account 07-1139. Should any additional fees be required for further consideration of the application and the enclosed information, the Commissioner is hereby authorized to charge such fees (or credit any overpayment) to Deposit Account 07-1139 (Ref. 135/003).

Respectfully submitted,



Cheryl L. Franke  
Registration No. 44,113

GERON CORPORATION  
230 Constitution Drive  
Menlo Park, CA 94025  
*Telephone: (650) 473-7748*  
*Fax: (650) 473-8654*

July 2, 2007

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Sheet	1	of	1	Application Number	10/804,822
				Filing Date	March 19, 2004
				First Named Inventor	Lawrence W. STANTON
				Art Unit	1632
				Examiner Name	Shin Lin CHEN
				Attorney Docket Number	135/003

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No.	Document Number Number-Kind-Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials	Cite No.	Foreign Patent Document Country Code-Number-Kind- Code	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, where relevant passages or relevant figures appear	T

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Trans
		ANISIMOV, S. et al., "SAGE identification of differentiation responsive genes in P19 embryonic cells induced to form cardiomyocytes in vitro," <i>Mech. Dev.</i> 117:25-74 (2002).	
		HARA, T. et al., "Identification of podocalyxin-like Protein 1 as a novel cell surface marker for hemangioblasts in the murine aorta-gonad-mesonephros region," <i>Immunity</i> 11:567-78 (1999).	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--